Sepriano, A <br/><br/>
Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.  [electronic resource] 

 -  Arthritis & rheumatology (Hoboken, N.J.)  11 2016 
 - 2671-2679 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2326-5205 
<br/><br/><label>Standard No.: </label>10.1002/art.39772  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--therapeutic use<br/>Adult<br/>Antibodies, Monoclonal--therapeutic use<br/>Antirheumatic Agents--therapeutic use<br/>Blood Sedimentation<br/>C-Reactive Protein--immunology<br/>Cohort Studies<br/>Deprescriptions<br/>Drug Therapy, Combination<br/>Etanercept--therapeutic use<br/>Female<br/>Humans<br/>Infliximab--therapeutic use<br/>Male<br/>Middle Aged<br/>Pain Measurement<br/>Prospective Studies<br/>Spondylarthritis--drug therapy<br/>Spondylarthropathies--drug therapy<br/>Time Factors<br/>Tumor Necrosis Factor-alpha--adverse effects